Development is an important component of our program; our focus is to provide training and other funding opportunities for the next generation of Parkinson’s disease researchers around the world. GP2 will offer these opportunities to the entire neurodegeneration community through the course of the program.
In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science.
ASAP Scientific Director, Randy Schekman, expresses his personal and professional connection with Parkinson's disease in a letter to the patient community, shared by patient advocate Benjamin Stecher.